TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Trial Details

NCT ID
NCT06088888
Phase
PHASE1
Sponsor
Shenzhen TargetRx Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • TGRX-678
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Willing to participate in the study with informed consent;
  • At least 18 years of age at the time of screening;
  • Diagnosis of CML-CPduring the screening period;
  • Intolerant or resistant to TKI treatments;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →